Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing

David McCall, Senior Editor, Nucleic Acid Insights, speaks to Jeske Smink, Senior Director, Head of Drug Substance, about Silence Therapeutics’ platform-based approach to developing targeted short interfering RNA-based therapies. They discuss the current state-of-the-art in oligonucleotide manufacturing and CMC, and explore the emerging alternatives to the traditional solid-phase synthesis approach.

Please enter your email to access content Read now